TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3496470

Group type: EXPERIMENTAL
Intervention: Nightly 160 mg trimethoprim and 800 mg sulfamethoxazole
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Three-day antibiotic treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 10-day antibiotic therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Suppressive antibiotics, treatment of asymptomatic urinary tract infections, full course antibiotic therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo, treatment of symptomatic urinary tract infection only, short course therapy
Number of subjects: 46
Study: 29052846

Group type: EXPERIMENTAL
Intervention: Internet treatment (IT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Face-to-face group treatment (GT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 116
Study: 27184591

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine, 0.3-0.4 mg·kg(‐1) ·h(‐1) (Group R)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (Group R)
Number of subjects: 49
Study: 25264990

Group type: EXPERIMENTAL
Intervention: Latanoprost/Timolol Fixed Combination (LTFC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Latanoprost and Timolol Gel-forming Solution Unfixed Combination (LTuFC)
Number of subjects: 90
Study: 23503739

Group type: EXPERIMENTAL
Intervention: activeTENS (transcutaneous electrical nerve stimulation during everyday activities)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control treatment (wearing the sock electrode with no stimulation)
Number of subjects: 29
Study: 21319355

Group type: EXPERIMENTAL
Intervention: 0.25 μg.kg⁻¹ remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 40
Study: 19145563

Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 4
Study: 17046300

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 5 or 10 mg montelukast (M)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (B) + 5 or 10 mg montelukast (M)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (B) + 9 microg formoterol (F)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15124662

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency at 15 W
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency at 30 W
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency at 15 W
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency at 30 W
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 26
Study: 11174813

Group type: EXPERIMENTAL
Intervention: Endograft aortic aneurysm (EAG) repair
Number of subjects: 368

Group type: COMPARATOR
Intervention: Conventional open surgical (COS) repair
Number of subjects: 368
Study: 10378674

Group type: EXPERIMENTAL
Intervention: Topitriol (calcitriol, 1,25-dihydroxyvitamin D3) cream (0.0025 or 0.005%; 25 and 50 microg/g concentration) administered topically twice a day. Doses evaluated: 500 and 1000 microg daily for 7 days prior to chemotherapy, and 2000 microg daily for 5 days prior and 5 days post‐chemotherapy.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7712314

Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingual GTN
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 mg/kg/h intravenous L‐arginine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2654792

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPM) 2.5 mg/kg in 5 doses plus dexamethasone (DXM) 0.2 mg/kg in 2 doses
Number of subjects: 69

Group type: COMPARATOR
Intervention: High-dose metoclopramide (HD-MCP) 10 mg/kg in 5 doses plus dexamethasone (DXM)
Number of subjects: 69
Study: 55523

Group type: EXPERIMENTAL
Intervention: CCNU followed by bleomycin
Number of subjects: 35

Group type: COMPARATOR
Intervention: CCNU, bleomycin, methotrexate, and vinblastine
Number of subjects: 35
Study: 31729622

Group type: EXPERIMENTAL
Intervention: Multispecies synbiotic (probiotics and prebiotics)
Number of subjects: 26
Study: 30548326

Group type: EXPERIMENTAL
Intervention: Aggressive Behavior Prevention Program (ABPP) implemented for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 29275582

Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules + Mosapride Citrate + Deanxit
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules + Mosapride Citrate + Shuganjieyu capsule
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules + Mosapride Citrate + Deanxit + Shuganjieyu capsule
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Deanxit
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (Lansoprazole Capsules + Mosapride Citrate)
Number of subjects: 125
Study: 25899477

Group type: EXPERIMENTAL
Intervention: Xbox Kinect
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stationary cycle
Number of subjects: 30
Study: 23653900

Group type: EXPERIMENTAL
Intervention: RelyX ARC (ARC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RLXU)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Maxcem Elite (MCE)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SeT (ST)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Preparations without restoration (WR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sound teeth (Control)
Number of subjects: 72
Study: 20473134

Group type: EXPERIMENTAL
Intervention: Amnestic multidomain MCI
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Nonamnestic multiple domain MCI
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Nonamnestic single domain MCI
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Amnestic single domain MCI
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Cognitive deficits in at least 1 domain
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Multiple cognitive domain deficits
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Isolated memory deficit
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Isolated nonmemory deficit
Number of subjects: 447
Study: 18374753

Group type: EXPERIMENTAL
Intervention: Combination of vascular endothelial growth factor (VEGF) and L‐arginine (6 g per day for 3 months)
Number of subjects: 19
Study: 16632816

Group type: EXPERIMENTAL
Intervention: Hypnosis (n = 26)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Attention-control (n = 26)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard of care control (n = 24)
Number of subjects: 76
Study: 12790506

Group type: EXPERIMENTAL
Intervention: Nitrous oxide sedation (NO)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 62
Study: 10780630

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 10
Study: 2124732

Group type: EXPERIMENTAL
Intervention: Diazepam enema (0.5 mg/kg bodyweight) in prone position
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diazepam enema (0.5 mg/kg bodyweight) in lateral position
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diazepam enema (0.5 mg/kg bodyweight)
Number of subjects: 14
Study: 6101337

Group type: EXPERIMENTAL
Intervention: H1 blocker (hydroxyzine HCl)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H1 plus H2 blocker (hydroxyzine HCl + cimetidine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: H2 blocker (cimetidine)
Number of subjects: 10
Study: 30592022

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study: 28256066

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (150 mg/m2 once per week for 3 of 4 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 200
Study: 27430714

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) alongside conventional intermittent home glucose monitoring (HGM)
Number of subjects: 324

Group type: COMPARATOR
Intervention: HGM alone
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: RT-CGM
Number of subjects: 324
Study: 25063045

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Tofacitinib (both doses)
Number of subjects: 1215
Study: 22209190

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 or 30 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lithium 900, 1200 or 1500 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 66
Study: 19160399

Group type: EXPERIMENTAL
Intervention: Concurrent ESS and CR
Number of subjects: 13

Group type: COMPARATOR
Intervention: CR only
Number of subjects: 13
Study: 17173906

Group type: EXPERIMENTAL
Intervention: High-security straws (HSSs)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Conventional straws
Number of subjects: 306
Study: 15885986

Group type: EXPERIMENTAL
Intervention: Piperacillin-sulbactam (PIP‐SBT)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PIP‐TAZ)
Number of subjects: 215
Study: 11819108

Group type: EXPERIMENTAL
Intervention: Hand-sutured anastomoses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biofragmentable anastomotic ring (BAR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stapled anastomoses
Number of subjects: 30
Study: 9857541

Group type: EXPERIMENTAL
Intervention: Ultrasound technique for prosthetic treatment planning and observation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard prosthetic treatment planning based on subjective estimation
Number of subjects: 180
Study: 8573425

Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Tiludronate 400 mg
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 2569665

Group type: EXPERIMENTAL
Intervention: Clobazam (Odipam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 7028088

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate eye drops
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate eye drops
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 39
Study: 30431383

Group type: EXPERIMENTAL
Intervention: HAVi administered alone
Number of subjects: 4374

Group type: EXPERIMENTAL
Intervention: HAVi administered concomitantly with other pediatric vaccines
Number of subjects: 4374
Study: 28087723

Group type: EXPERIMENTAL
Intervention: Prophylactic propranolol (0.5 mg/kg/dose every 12 hours)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 27518319

Group type: EXPERIMENTAL
Intervention: Itopride 100 mg t.d.s.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24813196

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa on cycle day 4 (CD4)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Corifollitropin alfa on cycle day 2 (CD2)
Number of subjects: 59
Study: 22366526

Group type: EXPERIMENTAL
Intervention: FT multimodal rehabilitation programme
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional perioperative care (non‐FT group)
Number of subjects: 99
Study: 20384754

Group type: EXPERIMENTAL
Intervention: Dual-depth fractional CO(2) resurfacing
Number of subjects: 15
Study: 18534230

Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (AAF)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control extensively hydrolyzed formula (EHF)
Number of subjects: 197
Study: 16003455

Group type: EXPERIMENTAL
Intervention: Self‐monitored, home‐based rehabilitation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Hospital‐based, outpatient rehabilitation
Number of subjects: 240
Study: 12430877

Group type: EXPERIMENTAL
Intervention: Total Therapy II (TT II) with thalidomide at a starting dose of 400 mg
Number of subjects: 231

Group type: COMPARATOR
Intervention: Total Therapy II (TT II) without thalidomide (data still blinded)
Number of subjects: 231
Study: 10071916

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 67
Study: 7480526

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 16
Study: 2147887

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 150 micrograms desogestrel (EE/DG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 75 micrograms gestodene (EE/GSD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both EE/DG and EE/GSD
Number of subjects: 0
Study: 7039666

Group type: EXPERIMENTAL
Intervention: Oral timolol (5 mg to 30 mg per day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of timolol and adrenaline
Number of subjects: 12
Study: 30892293

Group type: EXPERIMENTAL
Intervention: Ball-retained overdentures
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bar-retained overdentures
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Locator-retained overdentures
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chewing of hard food
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chewing of soft food
Number of subjects: 24
Study: 28619034

Group type: EXPERIMENTAL
Intervention: New community-based intervention model (NC model)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Traditional community intervention model (TC model)
Number of subjects: 901
Study: 26408273

Group type: EXPERIMENTAL
Intervention: sulodexide 500 lipasemic units twice daily
Number of subjects: 615

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: sulodexide
Number of subjects: 615

Group type: COMPARATOR
Intervention: sulodexide and placebo
Number of subjects: 615
Study: 23603824

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 243
Study: 20924753

Group type: EXPERIMENTAL
Intervention: TFMPP (0.94 mg/kg, oral)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19763062

Group type: EXPERIMENTAL
Intervention: Rub-and-spray method (group G, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (group C, n=10)
Number of subjects: 20
Study: 16673051

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 24
Study: 15090395

Group type: EXPERIMENTAL
Intervention: Group 1 (porcine graft fixed in porcine tibia)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group 2 (human hamstring graft and porcine tibia)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Group 3 (human graft and tibia)
Number of subjects: 3
Study: 11572892

Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor levels above the median
Number of subjects: 160
Study: 9786313

Group type: EXPERIMENTAL
Intervention: irinotecan 300 to 350 mg/m2 every 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: infusional 5-FU with or without leucovorin
Number of subjects: 0
Study: 8156337

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Thymopentin (in elderly patients)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (in elderly patients)
Number of subjects: 206
Study: 3047691

Group type: EXPERIMENTAL
Intervention: Experimental group with nursing intervention program including discussion of assessment data, identification of problems, and establishment of goals
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 103
Study: 28459350

Group type: EXPERIMENTAL
Intervention: Augmented feedback (aF) about ground-contact time (GCT) during 8 high-intensity interval sessions over 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group 1 (CG1) - trained with the intervention group but received no feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group 2 (CG2) - followed their own training routine
Number of subjects: 30
Study: 28060148

Group type: EXPERIMENTAL
Intervention: 2 mg ziv-aflibercept (0.08 mL) intravitreal injection
Number of subjects: 20
Study: 26335105

Group type: EXPERIMENTAL
Intervention: Completion axillary treatment (completion axillary lymph node dissection or axillary radiation therapy)
Number of subjects: 878

Group type: COMPARATOR
Intervention: No completion axillary treatment
Number of subjects: 878
Study: 22857386

Group type: EXPERIMENTAL
Intervention: basic numeric FOP label
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: numeric FOP label with 'high' and 'low' sodium content descriptors
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: detailed Traffic Light (TL) label with colour coding, content descriptors and numeric information
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: simple TL label with no numeric information
Number of subjects: 430

Group type: COMPARATOR
Intervention: control condition with no FOP label
Number of subjects: 430
Study: 21156974

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg (2 capsules) in recovery room, followed by celecoxib 200 mg (1 capsule) twice a day + placebo at bedtime for 3 days after surgery.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg (1 tablet) in recovery room, followed by 400 mg orally 3 times a day for 3 days after surgery.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo treatment (2 placebo capsules or 1 placebo tablet in recovery room, followed by placebo for 3 days after surgery).
Number of subjects: 180
Study: 19006062

Group type: EXPERIMENTAL
Intervention: Nasal packing after septoplasty
Number of subjects: 88

Group type: COMPARATOR
Intervention: No nasal packing after septoplasty
Number of subjects: 88
Study: 15814212

Group type: EXPERIMENTAL
Intervention: Clustered Care following blood collection (PCC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine care-giving tasks (RCC)
Number of subjects: 54
Study: 12459686

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Low-dose infusion (LDI)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Traditional epidural analgesia
Number of subjects: 1054
Study: 10488711

Group type: EXPERIMENTAL
Intervention: Hepatocellular carcinoma patients with non-cirrhotic livers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alcohol intake > or =30 g/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serological markers of HBV or HCV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No exposure to alcohol or tobacco and no serological markers of HBV or HCV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pathological changes in the non-tumorous liver
Number of subjects: 30
Study: 8729094

Group type: EXPERIMENTAL
Intervention: Diet rich in n-6 linoleic acid or n-3 alpha-linolenic acid with or without fish oil supplements (n-3 derivatives)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Diet rich in PUFA (either n-3 or n-6 or fish oils)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Increased dietary intake of PUFA
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Balanced dietary intake of PUFA
Number of subjects: 519
Study: 1908190

Group type: EXPERIMENTAL
Intervention: Acupuncture and transcutaneous stimulation analgesia supplemented by small doses of fentanyl (mean 1.2 micrograms/kg, SD 1.7)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Moderate-dose fentanyl anaesthesia (mean 22.9 micrograms/kg, SD 2.8)
Number of subjects: 29
Study: 6580492

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (N‐acetyl‐L‐cysteine) 1 hour before doxorubicin administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo 1 hour before doxorubicin administration
Number of subjects: 20
Study: 30938315

Group type: EXPERIMENTAL
Intervention: Immunoglobulin plus ciclosporin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin
Number of subjects: 0
Study: 29967037

Group type: EXPERIMENTAL
Intervention: Self-management (daily home BP monitoring and automated medication reduction via telemonitoring)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 91
Study: 27301277

Group type: EXPERIMENTAL
Intervention: Cladribine followed by rituximab
Number of subjects: 80
Study: 25364873

Group type: EXPERIMENTAL
Intervention: Insulin injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral antidiabetic drugs (OADs)
Number of subjects: 50
Study: 22409418

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.03% and 0.1%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pimecrolimus 1%
Number of subjects: 0
Study: 21140698

Group type: EXPERIMENTAL
Intervention: Prophylactic ilioinguinal nerve excision (INE)
Number of subjects: 97
Study: 16228107

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) 2 mg/kg daily for 12 months, then 1 mg/kg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Azathioprine (AZ) 2.5 mg/kg daily for 12 months, then 2 mg/kg daily
Number of subjects: 60
Study: 14602794

Group type: EXPERIMENTAL
Intervention: Estradiol-17 beta (E(2))
Number of subjects: 6
Study: 10757579

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with clonidine 2 microg/kg (1 ml/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain ropivacaine 0.2% (1 ml/kg)
Number of subjects: 40
Study: 8836275

Group type: EXPERIMENTAL
Intervention: Nebulized tetracaine 0.5 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nebulized saline
Number of subjects: 30